Cardiovascular disease: The price of a QALY—cost-effectiveness of statins in CKD

Nature Reviews Nephrology

Volumn 9, Issue 7, 2013, Pages 377-379

  Jha, Vivekanand ^a   Modi, Gopesh K ^b  

^a GEORGE INSTITUTE FOR GLOBAL HEALTH   (Australia)

^b Samarpan Kidney Institute and Research Center   (India)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN;

CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY FAILURE; ECONOMICS; FEMALE; HEART INFARCTION; HUMAN; MALE; NOTE; RHABDOMYOLYSIS; KIDNEY FAILURE, CHRONIC; MYOCARDIAL INFARCTION; STROKE;

FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY FAILURE, CHRONIC; MALE; MYOCARDIAL INFARCTION; PRAVASTATIN; RHABDOMYOLYSIS; STROKE;

EID: 84896550242     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2013.104     Document Type: Article

References (10)

1. United States Renal Data System. 2012 USRDS Annual Data Report: atlas of chronic kidney disease and end-stage renal disease in the United States. United States Renal Data System [online], http://www.usrds.org/atlas.aspx (2012).
2. Chronic Kidney Disease Prognosis Consortium. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 375, 2073–2081 (2010).
3. Tonelli, M. et al. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. Lancet 380, 807–814 (2012).
4. Lazar, L. D., Pletcher, M. J., Coxson, P. G., Bibbins-Domingo, K. & Goldman, L. Cost-effectiveness of statin therapy for primary prevention in a low-cost statin era. Circulation 124, 146–153 (2011).
5. Erickson, K. F. et al. Cost-effectiveness of statins for primary cardiovascular prevention in chronic kidney disease. J. Am. Coll. Cardiol. 61, 1250–1258 (2013).
6. Grosse, S. D. Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold. Expert Rev. Pharmacoecon. Outcomes Res. 8, 165–178 (2008).
7. Husereau, D. et al. Consolidated health economic evaluation reporting standards (CHEERS) statement. BMJ 346, f1049 (2013).
8. Nord, E., Pinto, J. L., Richardson, J., Menzel, P. & Ubel, P. Incorporating societal concerns for fairness in numerical valuations of health programmes. Health Econ. 8, 25–39 (1999).
9. Jha, V. et al. Chronic kidney disease: global dimension and perspectives. Lancet (in press).
10. Oliver, A. Accounting for the missing opportunity costs in incremental cost-outcome analysis. Appl. Health Econ. Health Policy 1, 191–196 (2002).